European Journal of Nuclear Medicine and Molecular Imaging

, Volume 37, Supplement 1, pp 86–103

Positron emission tomography tracers for imaging angiogenesis


    • Department of Nuclear MedicineMedical University Innsbruck
  • Ambros J. Beer
    • Department of Nuclear MedicineTechnische Universität München
  • Hui Wang
    • Department of Radiology, West China HospitalSichuan University
  • Xiaoyuan Chen
    • Laboratory of Molecular Imaging and Nanomedicine, National Institute of Biomedical Imaging and BioengineeringNational Institutes of Health

DOI: 10.1007/s00259-010-1503-4

Cite this article as:
Haubner, R., Beer, A.J., Wang, H. et al. Eur J Nucl Med Mol Imaging (2010) 37: 86. doi:10.1007/s00259-010-1503-4


Position emission tomography imaging of angiogenesis may provide non-invasive insights into the corresponding molecular processes and may be applied for individualized treatment planning of antiangiogenic therapies. At the moment, most strategies are focusing on the development of radiolabelled proteins and antibody formats targeting VEGF and its receptor or the ED-B domain of a fibronectin isoform as well as radiolabelled matrix metalloproteinase inhibitors or αvβ3 integrin antagonists. Great efforts are being made to develop suitable tracers for different target structures. All of the major strategies focusing on the development of radiolabelled compounds for use with positron emission tomography are summarized in this review. However, because the most intensive work is concentrated on the development of radiolabelled RGD peptides for imaging αvβ3 expression, which has successfully made its way from bench to bedside, these developments are especially emphasized.


Angiogenesis Vascular endothelial growth factor Fibronectin ED-B domain Integrin αvβ3 Matrix metalloproteinase Imaging Positron emission tomography

Copyright information

© Springer-Verlag 2010